KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO) Files An 8-K Regulation FD Disclosure

KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01

Regulation FD Disclosure.

On January 5, 2017, KaloBios Pharmaceuticals, Inc., (the Company)
reported that on January 4, 2017, the U.S. Food and Drug
Administration (FDA) released the minutes from a recent meeting
with the Company. In the minutes, FDA provided the Company
positive guidance regarding its development plans for
benznidazole for the treatment of Chagas disease, a neglected
tropical disease.

On January 5, 2017, the Company issued a press release, a copy of
which is being furnished as Exhibit 99.1 to this Report on Form
8-K and the contents of which are incorporated herein by

Item 9.01.

Financial Statements and Exhibits.


Exhibit No.



Press Release dated January 5, 2017

About KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO)

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems. It is engaged in developing monoclonal antibodies, lenzilumab, for the treatment of chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia both of which are rare hematologic cancers. It is exploring development of another of its monoclonal antibodies, ifabotuzumab, for the treatment of rare solid and hematologic cancers. Its KB001-A, is a Humaneered, PEGylated, anti-PcrV modified antibody fragment (Fab) antibody developed for the prevention and treatment of Pseudomonas aeruginosa (Pa), infections in mechanically ventilated patients and cystic fibrosis (CF), patients with chronic Pa lung infections.

KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO) Recent Trading Information

KaloBios Pharmaceuticals, Inc. (OTCMKTS:KBIO) closed its last trading session down -0.06 at 3.94 with shares trading hands.

An ad to help with our costs